Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Enfortumab Vedotin · Padcev Ejfv, PADCEV

Antibody-drug conjugate · Cytotoxic, directed at Nectin-4 · developed by Astellas

Approved FDA, Dec 2019
1 Registered trials

What is Enfortumab Vedotin?

Enfortumab vedotin is an antibody-drug conjugate in which a human IgG1 kappa antibody binds Nectin-4, an adhesion protein on the cell surface. After the complex is internalized, the microtubule-disrupting agent MMAE is released through protease-cleavage of its linker, leading to cell cycle arrest and apoptosis. It is used in the treatment of muscle-invasive bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Padcev Ejfv, PADCEV, ASG-22CE
Drug type
Antibody-drug conjugate
Targets
Nectin-4
Mechanism
Cytotoxic, directed at Nectin-4
Pathways
microtubule disruption, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Astellas
In trials of
PFE
FDA status
Approved as Padcev Ejfv (December 18, 2019), BLA761137 · FDA label
UNII
DLE8519RWM

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 4, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07475806 Phase 2 Muscle-invasive Bladder Cancer Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Muscle-invasive Bladder Cancer

Other drugs acting on NECTIN4

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.